Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years

29th April 2026 Uncategorised 0

As regulatory delays continue to plague Regeneron’s Eylea franchise, quarterly sales for the eye disease medicine have dropped below $1 billion for the first time since the second quarter of 2018.

More: Regeneron's quarterly sales of Eylea drop below B for the first time in 8 years
Source: fierce